(5S)-5-methyl-1,3-oxazolidin-2-one

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: By reaction and treatment in the same manner as in Example 149 and using [4-bromo-2-(1,1-dioxoisothiazolidin-2-yl)phenyl][4-(5-ethyl-3-methylpyridin-2-yl)piperazin-1-yl]methanone (507 mg) described in Preparation Example 180 and (S)-5-methyloxazolidin-2-one (121 mg) described in Preparation Example 42, the title compound (437 mg) was obtained. By reaction and treatment in the same manner as in Example 149 described in Preparation Example 42

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: By reaction and treatment in the same manner as in Example 149 and using [4-bromo-2-(1,1-dioxoisothiazolidin-2-yl)phenyl][4-(5-cyclopropyl-3-methylpyridin-2-yl)piperazin-1-yl]methanone (519 mg) described in Preparation Example 179 and (S)-5-methyloxazolidin-2-one (121 mg) described in Preparation Example 42, the title compound (457 mg) was obtained. By reaction and treatment in the same manner as in Example 149 described in Preparation Example 42

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: By reaction and treatment in the same manner as in Example 110 and using [4-bromo-2-(1,1-dioxoisothiazolidin-2-yl)phenyl][4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone (493 mg) described in Preparation Example 118 and (S)-5-methyloxazolidin-2-one (121 mg) described in Preparation Example 42, the title compound (323 mg) was obtained. By reaction and treatment in the same manner as in Example 110 described in Preparation Example 42

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: By reaction and treatment in the same manner as in Example 149 and using [4-(5-ethyl-3-methylpyridin-2-yl)piperazin-1-yl](4-iodophenyl)methanone (435 mg) described in Preparation Example 177 and (S)-5-methyloxazolidin-2-one (121 mg) described in Preparation Example 42, the title compound (330 mg) was obtained. By reaction and treatment in the same manner as in Example 149 described in Preparation Example 42

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: By reaction and treatment in the same manner as in Example 149 and using (4-iodophenyl)[4-(3,5,6-trimethylpyridin-2-yl)piperazin-1-yl]methanone (435 mg) described in Preparation Example 176 and (S)-5-methyloxazolidin-2-one (121 mg) described in Preparation Example 42, the title compound (308 mg) was obtained. By reaction and treatment in the same manner as in Example 149 described in Preparation Example 42

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: By reaction and treatment in the same manner as in Example 1 and using (6-bromopyridin-3-yl)[4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone (748 mg) described in Preparation Example 73 and (S)-5-methyloxazolidin-2-one (243 mg) described in Preparation Example 42, the title compound (706 mg) was obtained. By reaction and treatment in the same manner as in Example 1 described in Preparation Example 42

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: By reaction and treatment in the same manner as in Example 1 and using (4-bromo-2,6-difluorophenyl)[4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone (615 mg) described in Preparation Example 60 and (S)-5-methyloxazolidin-2-one (243 mg) described in Preparation Example 42, the title compound (337 mg) was obtained. By reaction and treatment in the same manner as in Example 1 described in Preparation Example 42

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: By reaction and treatment in the same manner as in Example 1 and using (4-bromo-2-fluorophenyl)[4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl]methanone (498 mg) described in Preparation Example 65 and (S)-5-methyloxazolidin-2-one (197 mg) described in Preparation Example 42, the title compound (429 mg) was obtained. By reaction and treatment in the same manner as in Example 1 described in Preparation Example 42

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: By reaction and treatment in the same manner as in Example 149 and using [4-(5-cyclopropyl-3-methylpyridin-2-yl)piperazin-1-yl](4-iodophenyl)methanone (447 mg) described in Preparation Example 97 and (S)-5-methyloxazolidin-2-one (121 mg) described in Preparation Example 42, the title compound (344 mg) was obtained. By reaction and treatment in the same manner as in Example 149 described in Preparation Example 42

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: By reaction and treatment in the same manner as in Example 149 and using [4-(3,5-dicyclopropylpyridin-2-yl)piperazin-1-yl](4-iodophenyl)methanone (473 mg) described in Preparation Example 95 and (S)-5-methyloxazolidin-2-one (121 mg) described in Preparation Example 42, the title compound (343 mg) was obtained. By reaction and treatment in the same manner as in Example 149 described in Preparation Example 42

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: By reaction and treatment in the same manner as in Example 111 and using (4-bromo-2-methanesulfonylphenyl)[4-(3,5-dicyclopropylpyridin-2-yl)piperazin-1-yl]methanone (400 mg) described in Preparation Example 89 and (S)-5-methyloxazolidin-2-one (80.2 mg) described in Preparation Example 42, the title compound (258.4 mg) was obtained. By reaction and treatment in the same manner as in Example 111 described in Preparation Example 42